Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco
About this trial
The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
Eligibility criteria
Qualifiers
Inclusion is based on presenting acuity, not ulcer size.
Inclusion of 20/40 = 6/12 = 0.3 Log MAR and 20/400 = 3/60 = +1.3 Log MAR.
Smear or culture positive for fungal keratitis, any length.
Age 18 years.
Disqualifiers
Co-infection with bacterial or viral keratitis.
Corneal perforation.
Requiring therapeutic keratoplasty for fungal keratitis.
Unwilling or unable to follow up (e.g., living too far from hospital).
Trial design
Treatments tested in this trial
- Cyclosporine A
- Placebo Comparator: Placebo
Treatment groups
150 Participants
are divided into 3 treatment groupsSponsors and collaborators
University of California, San Francisco
Lead sponsor
Aravind Eye Hospitals, India
Collaborator
Aravind Eye Care System
Collaborator
Source ClinicalTrials.gov